Clinic Roundup

• Lithera Inc., of San Diego, said the first patient was treated with LIPO-202 (salmeterol xinafoate for injection) in its 500-patient Phase IIb RESET trial. LIPO-202 is Lithera's lead candidate designed to produce localized reduction of subcutaneous fat.